We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

35 hedge funds and large institutions have $176M invested in La Jolla Pharmaceutical Company in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

322% more call options, than puts

Call options by funds: $333K | Put options by funds: $79K

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

145% more capital invested

Capital invested by funds: $72.1M → $176M (+$104M)

21% more funds holding

Funds holding: 2935 (+6)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
35
Holders Change
+6
Holders Change %
+20.69%
% of All Funds
0.93%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.11%
New
13
Increased
8
Reduced
8
Closed
5
Calls
$333K
Puts
$79K
Net Calls
+$254K
Net Calls Change
+$254K
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$39.6M +$2.76M +232,925 +12%
BC
2
Broadfin Capital
New York
$20.7M +$170K +14,324 +1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$20.4M
RI
4
RTW Investments
New York
$19.6M +$12.6M +1,064,247 New
Franklin Resources
5
Franklin Resources
California
$17M
VAM
6
Visium Asset Management
New York
$10.6M
BBA
7
Baker Bros. Advisors
New York
$7.78M
Vanguard Group
8
Vanguard Group
Pennsylvania
$6.04M +$113K +9,500 +3%
PA
9
Perceptive Advisors
New York
$5.33M +$462K +38,955 +16%
GTC
10
Ghost Tree Capital
New York
$5.28M +$3.4M +286,053 New
ACA
11
Avoro Capital Advisors
New York
$4.55M +$2.93M +246,499 New
GIM
12
Granahan Investment Management
Massachusetts
$3.59M +$2.31M +194,578 New
BGA
13
Belmont Global Advisors
Texas
$3.42M -$318K -26,800 -13%
SFM
14
Sphera Funds Management
Israel
$1.85M -$1.46M -123,100 -55%
EI
15
EAM Investors
California
$1.77M +$1.14M +96,064 New
Morgan Stanley
16
Morgan Stanley
New York
$1.37M +$385K +32,476 +77%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$1.22M +$782K +65,878 New
RA
18
Royce & Associates
New York
$1.11M +$712K +60,000 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.05M +$254K +21,390 +60%
BIT
20
BlackRock Institutional Trust
California
$816K +$525K +44,209 New
BFA
21
BlackRock Fund Advisors
California
$598K +$63.3K +5,333 +20%
Deutsche Bank
22
Deutsche Bank
Germany
$553K +$356K +30,000 New
PAWC
23
P.A.W. Capital
Connecticut
$461K +$297K +25,000 New
Creative Planning
24
Creative Planning
Kansas
$454K +$292K +24,600 New
TMC
25
Trellus Management Company
Florida
$316K -$304K -25,648 -60%

LJPC Hedge Fund Activity: Q4 2014 in Review

35 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2014, worth a combined $176M — up 145% from $72.1M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LJPC positions and 5 closed out — a net gain of 8 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.4M. The largest seller was Iguana Healthcare Management, exiting entirely with an estimated $1.73M sold.

  • 35 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2014, up from 29 in Q3 2014.
  • Funds reported $176M of La Jolla Pharmaceutical Company stock for Q4 2014, up 145% quarter-over-quarter.
  • 13 funds opened new La Jolla Pharmaceutical Company positions in Q4 2014 and 5 closed out, a net change of +8 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q4 2014 was Ghost Tree Capital, an estimated $3.4M added.
  • The largest La Jolla Pharmaceutical Company seller in Q4 2014 was Iguana Healthcare Management, an estimated $1.73M sold.

Based on aggregated 13F filings for Q4 2014.